BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
News | 03. 28. 2012
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
